Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Times Interest Earned: 2014-2025

Historic Times Interest Earned for Zevra Therapeutics (ZVRA) over the last 11 years, with Sep 2025 value amounting to $2.02.

  • Zevra Therapeutics' Times Interest Earned rose 117.10% to $2.02 in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.66, marking a year-over-year increase of 27.32%. This contributed to the annual value of -$11.84 for FY2024, which is 64.19% up from last year.
  • Zevra Therapeutics' Times Interest Earned amounted to $2.02 in Q3 2025, which was up 105.71% from -$35.36 recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Times Interest Earned ranged from a high of $364.56 in Q2 2021 and a low of -$689.31 during Q2 2022.
  • Over the past 3 years, Zevra Therapeutics' median Times Interest Earned value was -$20.05 (recorded in 2023), while the average stood at -$23.48.
  • The largest annual percentage gain for Zevra Therapeutics' Times Interest Earned in the last 5 years was 16,729.21% (2021), contrasted with its biggest fall of 35,406.82% (2021).
  • Over the past 5 years, Zevra Therapeutics' Times Interest Earned (Quarterly) stood at -$568.40 in 2021, then surged by 90.54% to -$53.78 in 2022, then skyrocketed by 62.72% to -$20.05 in 2023, then spiked by 64.95% to -$7.03 in 2024, then soared by 117.10% to $2.02 in 2025.
  • Its Times Interest Earned stands at $2.02 for Q3 2025, versus -$35.36 for Q2 2025 and -$2.72 for Q1 2025.